Download Mendeley(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
Kim, D., Wang, L., Beconi, M., Eiermann, G.J., Fisher, M.H., He, H., Hickey, G.J., Kowalchick, J.E., Leiting, B., Lyons, K., Marsilio, F., McCann, M.E., Patel, R.A., Petrov, A., Scapin, G., Patel, S.B., Roy, R.S., Wu, J.K., Wyvratt, M.J., Zhang, B.B., Zhu, L., Thornberry, N.A., Weber, A.E.(2005) J Med Chem 48: 141-151
- PubMed: 15634008 Search on PubMed
- DOI: https://doi.org/10.1021/jm0493156
- Primary Citation Related Structures:
1X70 - PubMed Abstract:
A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC(50) = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.
- Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. dooseop_kim@merck.com
Organizational Affiliation:
